Comparison of Population Characteristics in Real-World Clinical Oncology Databases in the US: Flatiron Health, SEER, and NPCR

#	Paper	IF	Citations
96	Using electronic health record data to identify comparator populations for comparative effectiveness research. *Journal of Medical Economics*, **2020**, 23, 1618-1622	2.4	3
95	Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung Cancer. *Oncologist*, **2020**, 25, 867-877	5.7	5
94	Clinical Impact of Adherence to NCCN Guidelines for Biomarker Testing and First-Line Treatment in Advanced Non-Small Cell Lung Cancer (aNSCLC) Using Real-World Electronic Health Record Data. *Advances in Therapy*, **2021**, 38, 1552-1566	4.1	3
93	Penalized regression for left-truncated and right-censored survival data.		
92	The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies. *European Journal of Haematology*, **2021**, 106, 662-672	3.8	10
91	Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study. *Cancers*, **2021**, 13,	6.6	8
90	Characterization of a Real-World Response Variable and Comparison with RECIST-Based Response Rates from Clinical Trials in Advanced NSCLC. *Advances in Therapy*, **2021**, 38, 1843-1859	4.1	2
89	Characterizing the Anticancer Treatment Trajectory and Pattern in Patients Receiving Chemotherapy for Cancer Using Harmonized Observational Databases: Retrospective Study. *JMIR Medical Informatics*, **2021**, 9, e25035	3.6	1
88	Evaluating eligibility criteria of oncology trials using real-world data and AI. *Nature*, **2021**, 592, 629-633	50.4	20
87	Adherence to National Comprehensive Cancer Network ALK Testing Guidelines for Patients with Advanced Non-Small Cell Lung Cancer in U.S. Community Medical Centers. *Oncologist*, **2021**, 26, e1050-e1057	5.7	5
86	Incorporating propensity scores for evidence synthesis under bayesian framework: review and recommendations for clinical studies. *Journal of Biopharmaceutical Statistics*, **2021**, 1-22	1.3	6
85	Real-world renal function among patients with multiple myeloma in the United States. *Blood Cancer Journal*, **2021**, 11, 99	7	1
84	Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2- metastatic breast cancer. *Current Medical Research and Opinion*, **2021**, 37, 1179-1187	2.5	5
83	Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor-Based Therapy in Patients With Advanced Non-Small-Cell Lung Cancer. *JAMA Oncology*, **2021**, 7, 937-939	13.4	17
82	Differential frequency in imaging-based outcome measurement: Bias in real-world oncology comparative-effectiveness studies. *Pharmacoepidemiology and Drug Safety*, **2021**,	2.6	1
81	Emulating Control Arms for Cancer Clinical Trials Using External Cohorts Created From Electronic Health Record-Derived Real-World Data. *Clinical Pharmacology and Therapeutics*, **2021**,	6.1	1
80	Penalized regression for left-truncated and right-censored survival data. *Statistics in Medicine*, **2021**, 40, 5487-5500	2.3	3

79	Real-world association of HER2/ concordance with trastuzumab clinical benefit in advanced esophagogastric cancer. *Future Oncology*, **2021**, 17, 4101-4114	3.6	2
78	Real-world characteristics and outcomes of advanced non-small-cell lung cancer patients with exon 19 deletions or exon 21 mutations. *Future Oncology*, **2021**, 17, 2867-2881	3.6	0
77	Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma. *Lung Cancer*, **2021**, 159, 107-110	5.9	2
76	Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States. *Cancers*, **2021**, 13,	6.6	1
75	Cost-minimization analysis of biweekly dosing of cetuximab and FOLFIRI compared with panitumumab and FOLFOX for first-line treatment of patients with KRAS wild-type metastatic colorectal cancer in the United States. *Journal of Medical Economics*, **2021**, 24, 1164-1172	2.4	
74	The value of innovation: association between improvements in survival of advanced and metastatic non-small cell lung cancer and targeted and immunotherapy. *BMC Medicine*, **2021**, 19, 209	11.4	0
73	Impact of the COVID-19 pandemic on treatment patterns for US patients with metastatic solid cancer. **2021**,		
72	Study of patient characteristics, treatment patterns, testing patterns and outcomes in real-world patients with m non-small cell lung cancer. *Current Medical Research and Opinion*, **2021**, 1-9	2.5	0
71	Clinical trial representativeness and treatment intensity in a real-world sample of women with early stage breast cancer. *Breast Cancer Research and Treatment*, **2021**, 190, 531-540	4.4	0
70	Bayesian additional evidence for decision making under small sample uncertainty. *BMC Medical Research Methodology*, **2021**, 21, 221	4.7	0
69	Approaches for Enhanced Extrapolation of Long-Term Survival Outcomes Using Electronic Health Records of Patients With Cancer.. *Value in Health*, **2022**, 25, 230-237	3.3	0
68	Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid Cancers. *JAMA Oncology*, **2021**,	13.4	6
67	Characterizing the Anticancer Treatment Trajectory and Pattern in Patients Receiving Chemotherapy for Cancer Using Harmonized Observational Databases: Retrospective Study (Preprint).		
66	Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer. *JAMA Network Open*, **2021**, 4, e2134299	10.4	5
65	Anaplastic lymphoma kinase rearrangement prevalence in patients with advanced non-small cell lung cancer in the United States: retrospective real world data. *Oncotarget*, **2021**, 12, 2308-2315	3.3	0
64	Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. *Clinical Drug Investigation*,	3.2	1
63	Understanding Factors Associated With Anaplastic Lymphoma Kinase Testing Delays in Patients With Non-Small Cell Lung Cancer in a Large Real-World Oncology Database. *Archives of Pathology and Laboratory Medicine*, **2021**,	5	0
62	Accounting for delayed entry in analyses of overall survival in clinico-genomic databases.. *Cancer Epidemiology Biomarkers and Prevention*, **2022**,	4	0

61	Dynamic Prediction of Near-Term Overall Survival in Patients with Advanced NSCLC Based on Real-World Data.. *Cancers*, **2022**, 14,	6.6	0
60	Real-world data prognostic model of overall survival in patients with advanced NSCLC receiving anti-PD-1/PD-L1 immune checkpoint inhibitors as second-line monotherapy.. *Cancer Reports*, **2022**, e1578	1.5	0
59	Trends in Use of Next-Generation Sequencing in Patients With Solid Tumors by Race and Ethnicity After Implementation of the Medicare National Coverage Determination. *JAMA Network Open*, **2021**, 4, e2138219	10.4	2
58	Impact of the COVID-19 Pandemic on Treatment Patterns for Patients with Metastatic Solid Cancer in the United States. *Journal of the National Cancer Institute*, **2021**,	9.7	2
57	Exploring racial disparities in treatment patterns and outcomes for patients with multiple myeloma using real world data.. *Blood Cancer Journal*, **2022**, 12, 65	7	1
56	Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer Types.. *Advances in Therapy*, **2022**, 1	4.1	1
55	Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis.. *Blood Cancer Journal*, **2022**, 12, 46	7	3
54	Real-World Progression-Free Survival as an Endpoint in Advanced Non-Small-Cell Lung Cancer: Replicating Atezolizumab and Docetaxel Arms of the OAK Trial Using Data Derived From Electronic Health Records.		0
53	Concordance of Clinician-Documented and Imaging Response in Patients With Stage IV Non-Small Cell Lung Cancer Treated With First-Line Therapy.. *JAMA Network Open*, **2022**, 5, e229655	10.4	0
52	Real-World Treatment Patterns and Outcomes of Mantle Cell Lymphoma.. *Blood Advances*, **2022**,	7.8	1
51	T-DM1 after Pertuzumab plus Trastuzumab: Treatment Sequence-Induced Selection Bias in HER2-Positive Metastatic Breast Cancer. *Cancers*, **2022**, 14, 2468	6.6	0
50	Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non Small Cell Lung Cancer. *JAMA Network Open*, **2022**, 5, e2214046	10.4	0
49	Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy. *Journal of Cancer Research and Clinical Oncology*,	4.9	0
48	Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer. *Nature Communications*, **2022**, 13,	17.4	1
47	Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic period. *Leukemia*,	10.7	1
46	Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors. *Urologic Oncology: Seminars and Original Investigations*, **2022**,	2.8	
45	Left truncation in linked data: A practical guide to understanding left truncation and applying it using SAS and R. *Pharmaceutical Statistics*,	1	
44	Advancing precision oncology with large, real-world genomics and treatment outcomes data. *Nature Medicine*,	50.5	

43	Adherence to guidelines-recommended diagnostic testing was associated with overall survival in patients with diffuse large B-cell lymphoma after rituximab-based treatment: an observational cohort study.	
42	A machine learning framework supporting prospective clinical decisions applied to risk prediction in oncology. **2022**, 5,	0
41	Time to treatment initiation and its impact on real-world survival in metastatic colorectal cancer and pancreatic cancer.	
40	A Real-World Data Retrospective Cohort Study of Low Estrogen Receptor-Positive Early Breast Cancer: Natural History and Treatment Outcomes. Volume 14, 199-210	
39	Racial inequities in second-line treatment and overall survival among patients with metastatic breast cancer.	0
38	Characterizing the Shifting Real-World Treatment Landscape by PD-L1 Testing Status and Expression Level in Advanced Non-Small Cell Lung Cancer.	
37	Assessing Oncologists Adoption of Biomarker Testing in Metastatic Colorectal Cancer Using Real World Data.	0
36	ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer. **2022**, 13,	0
35	A meta-analytic framework to adjust for bias in external control studies.	0
34	Telemedicine use among patients with metastatic breast cancer during the COVID -19 pandemic: Differences by race, age, and region.	0
33	Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real World.	0
32	Longitudinal assessment of ROPRO as an early indicator of overall survival in oncology clinical trials: a retrospective analysis.	0
31	Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2 metastatic breast cancer. **2022**, 8,	2
30	Treatment outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma: a real world study. **2022**, 22,	0
29	Machine learning models for identifying predictors of clinical outcomes with first-line immune checkpoint inhibitor therapy in advanced non-small cell lung cancer. **2022**, 12,	0
28	Real-world ALK Testing Trends in Patients with Advanced Non-small Cell Lung Cancer in the United States. **2022**,	0
27	Real-World Outcomes and Prognostic Factors Among Patients with Advanced Non-Small Cell Lung Cancer and High PD-L1 Expression Treated with Immune Checkpoint Inhibitors as First-Line Therapy. Volume 14, 3191-3202	0
26	TP53 Co-Mutation Status Association with Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer. **2022**, 14, 6127	0

25	Emulating Randomized Controlled Trials with Hybrid Control Arms in Oncology: A Case Study.	0
24	Comparison of Population Characteristics in Real-World Clinical Oncology Databases in the US: Flatiron Health-Foundation Medicine Clinico-Genomic Databases, Flatiron Health Research Databases, and the National Cancer Institute SEER Population-Based Cancer Registry.	0
23	Association Between Age and Survival Trends in Advanced Non‐Small Cell Lung Cancer After Adoption of Immunotherapy.	1
22	Systematic analysis of off-label and off-guideline cancer therapy usage in a real-world cohort of 153,122 U.S. patients.	0
21	Receipt of Targeted Therapy and Survival Outcomes in Patients With Metastatic Colorectal Cancer. **2023**, 6, e2250030	0
20	Real-world comparison of survival outcomes with cisplatin versus carboplatin in patients with limited-stage small-cell lung cancer. **2023**, 35, 100686	0
19	Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis.	0
18	Uptake of Maintenance Immunotherapy and Changes in Upstream Treatment Selection Among Patients With Urothelial Cancer. **2023**, 6, e238395	0
17	Harnessing Real-World Evidence to Advance Cancer Research. **2023**, 30, 1844-1859	0
16	Real-World Molecular Biomarker Testing Patterns and Results for Advanced Gastroesophageal Cancers in the United States. **2023**, 30, 1869-1881	0
15	A Real-World Data Retrospective Cohort Study of HER2-positive, Early-Stage Breast Cancer in Patients 70 Years of Age or Older: Natural History, Treatment Patterns, and Outcomes. **2023**,	0
14	The Association Between Baseline Hepatic or Renal Function and Clinical Outcomes for Patients With Non-Small Cell Lung Cancer Treated With a PD -1/PD- L1 Blocking Antibody Using Real-World and Trial Data. **2023**, 113, 1139-1149	0
13	Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval. **2023**, 9, 567	0
12	Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data. **2023**, 11, e006464	0
11	Chemoimmunotherapy vs. Immunotherapy for First Line Treatment of Advanced Non‐Small Cell Lung Cancer With a PD-L1 Expression ≥50% or ≥90%. **2023**,	0
10	Approach to Machine Learning for Extraction of Real-World Data Variables from Electronic Health Records.	1
9	A hybrid approach to scalable real-world data curation by machine learning and human experts.	0
8	Replication of Real-World Evidence in Oncology Using Electronic Health Record Data Extracted by Machine Learning. **2023**, 15, 1853	0

7	Association between posttreatment ɑ-fetoprotein reduction and outcomes in real-world US patients with advanced hepatocellular carcinoma.	1
6	A real-world data analysis of predictors of early mortality after a diagnosis of multiple myeloma.	0
5	Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database study. 1-12	0
4	Real-World Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Stage III or IV Classic Hodgkin Lymphoma Treated With Frontline ABVD: A Retrospective Database Review in the United States. **2023**,	0
3	Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison. **2023**, 179, 107186	0
2	Real-World Outcomes Following First-Line Treatment in Patients with Advanced Ovarian Cancer with Multiple Risk Factors for Disease Progression who Received Maintenance Therapy or Active Surveillance.	0
1	Impact of obesity on chemotherapy dosing of carboplatin and survival of women with ovarian cancer.	0